We use cookies to see how investors use El Fondo and make its tools, data and markets better for you. You can accept or reject; essential cookies always stay on. Privacy Policy
Trades about 308% below its sector, cheaper than its peers on earnings.
Anxo Pharmaceutical Co., Ltd. functions as a specialized enterprise in the pharmaceutical sector. This company is actively involved in the research, production, and global distribution of various medicinal products, catering to both healthcare professionals and individual patients, particularly within Taiwan and across international markets. Its comprehensive product catalog features both prescription-only drugs and over-the-counter remedies, addressing a broad spectrum of therapeutic needs. These include cardiovascular health, metabolic disorders, conditions affecting the central nervous system, diabetes management, respiratory ailments, anti-infective treatments, dermatological issues, nephrology, urology, and orthopedics, among others. More specifically, Anxo supplies agents for antidiabetic and dyslipidemic conditions, supports cardiovascular and circulatory systems, offers therapies for the nervous system, addresses hepatological and gastroenterological concerns, provides anti-infective and antiviral agents, and assists with hemodialysis and urinary system treatments. Additionally, their offerings cover respiratory system and antihistamine applications, various analgesics, and other specialized medications, including a range of injectable pharmaceuticals. Established in 2003, the company's main operational base is situated in Taipei, Taiwan.
Loading the full price history…
Run your own numbersPast performance is not a forecast.
Save 6677.TWO and get told when something moves.
Get updates
A clear, direct weekly summary.
Learn the fundamentals behind this asset.
A stock is a fraction of ownership in a real company. Buy one share and you own a piece (usually a tiny piece) of every desk, factory, contract and brand the company runs. The price moves because the market keeps revising what that whole pie is worth.
The price-to-earnings ratio is how much investors are paying for one dollar of a company's profit. A multiple, never an absolute. Always compared to something: a sector, a region, the company's own past.
Dividend yield is the annual income a stock or ETF pays out, expressed as a percentage of what you paid for it. It is the visible part of total return: the cash that lands in your account every quarter, and the lever most retail investors actually feel.
Market cap is shares times price. A simple formula that produces wildly unequal numbers: a single US tech name can be worth more than every company on a LATAM exchange combined.
